Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles

from Oncology Data Advisor · host i3 Health

In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.

Episode metadata supplied by the publisher feed · Published Oct 20, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles

0:00 11:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 11 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on October 20, 2023.

Can I download this Oncology Data Advisor episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!